Impairment of glutathione function in the brain is linked to loss of neurons during aging and to neurological diseases including Parkinson's disease and Alzheimer's disease
In a foundational 2009 study, Li and colleagues found that GLP-1R stimulation preserved both cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism [5]
For instance, liraglutide results in an average of 8% weight loss after 56 weeks, and tirzepatide can reduce body weight by as much as 21% in certain individuals
Ketamine abuse potential and use disorder
Landscapes Health & Medical Sciences (AREA) Chemical & Material Sciences (AREA) Life Sciences & Earth Sciences (AREA) General Health & Medical Sciences (AREA) Medicinal Chemistry (AREA) Veterinary Medicine (AREA) Pharmacology & Pharmacy (AREA) Public Health (AREA) Animal Behavior & Ethology (AREA) Organic Chemistry (AREA) Epidemiology (AREA) Bioinformatics & Cheminformatics (AREA) Engineering & Computer Science (AREA) Proteomics, Peptides & Aminoacids (AREA) Endocrinology (AREA) Gastroenterology & Hepatology (AREA) Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA) General Chemical & Material Sciences (AREA) Chemical Kinetics & Catalysis (AREA) Immunology (AREA) Molecular Biology (AREA) Biochemistry (AREA) Biophysics (AREA) Genetics & Genomics (AREA) Toxicology (AREA) Zoology (AREA) Reproductive Health (AREA) Gynecology & Obstetrics (AREA) Diabetes (AREA) Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA) Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA) Peptides Or Proteins (AREA) Abstract Multiple agent therapy for treatment of sexual dysfunction, including male erectile dysfunction, with sequential administration a type V phosphodiesterase inhibitor (PDE-5), such as sildenafil, preferably wherein the PDE-5 inhibitor is administered by oral dose means, and a melanocortin 3 and/or 4 receptor agonist, such as Ac-Nle-cyclo(-Asp-His-D-Phe-Arg-Trp-Lys)-OH (PT-141) preferably wherein the PT-141 is formulated for and administered by intranasal means, and further preferably wherein the PDE-5 inhibitor is administered prior to PT-141
